Eli Lilly Stock Falls Amid $2 Billion Acquisition Deal

Eli Lilly's stock price has declined as the company nears a $2 billion deal to acquire Kelonia, a developer of blood cancer therapies. Despite the potential strategic benefits of expanding its oncology portfolio, the market reaction suggests investor caution regarding the acquisition's valuation or integration challenges. The deal is expected to be finalized soon, marking a significant move for Eli Lilly in the competitive pharmaceutical landscape.